AP
BMRN icon

Appleton Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Appleton Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,790
Closed -$233K – 292
2021
Q2 		$233K Sell
2,790
-635
-19% -$50.3K 0.02% 275
2021
Q1 		$259K Sell
3,425
-1,269
-27% -$104K 0.02% 256
2020
Q4 		$412K Sell
4,694
-2,485
-35% -$197K 0.04% 205
2020
Q3 		$546K Sell
7,179
-530
-7% -$53.6K 0.06% 176
2020
Q2 		$951K Buy
7,709
+966
+14% +$96K 0.11% 137
2020
Q1 		$570K Buy
6,743
+603
+10% +$52K 0.08% 157
2019
Q4 		$519K Buy
6,140
+515
+9% +$38.9K 0.06% 190
2019
Q3 		$379K Sell
5,625
-785
-12% -$60.5K 0.05% 216
2019
Q2 		$549K Buy
6,410
+21
+0.3% +$1.8K 0.07% 181
2019
Q1 		$568K Buy
6,389
+1,348
+27% +$125K 0.08% 173
2018
Q4 		$429K Sell
5,041
-405
-7% -$38.5K 0.06% 187
2018
Q3 		$528K Buy
5,446
+1,096
+25% +$109K 0.07% 182
2018
Q2 		$410K Buy
+4,350
New +$381K 0.06% 199

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Appleton Partners's BMRN Position: Q3 2021 in Review

Appleton Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 2,790 shares — an estimated $233K sold.

Appleton Partners first reported a position in BMRN in Q2 2018 and held it in 13 quarters. The position peaked at $951K in Q2 2020. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

  • Appleton Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Appleton Partners sold 2,790 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $233K.
  • Appleton Partners first reported a position in BioMarin Pharmaceuticals in Q2 2018 and held it in 13 quarters.
  • Appleton Partners's BioMarin Pharmaceuticals position peaked at $951K in Q2 2020.
  • 511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Appleton Partners's 13F filing for Q3 2021, filed 14 Oct 2021.